CYP2A6
Reaktivität: Human
WB, ELISA
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Western Blot (1-2 μg/mL) The optimal working dilution should be determined by the end user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
In PBS (0.08 % sodium azide)
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20°C. Aliquot to avoid repeated freezing and thawing.
Higashi, Nakajima, Katoh, Tokudome, Yokoi: "Inhibitory effects of neurotransmitters and steroids on human CYP2A6." in: Drug metabolism and disposition: the biological fate of chemicals, Vol. 35, Issue 4, pp. 508-14, (2007) (PubMed).
Audrain-McGovern, Al Koudsi, Rodriguez, Wileyto, Shields, Tyndale: "The role of CYP2A6 in the emergence of nicotine dependence in adolescents." in: Pediatrics, Vol. 119, Issue 1, pp. e264-74, (2007) (PubMed).
Swan, Benowitz, Lessov, Jacob, Tyndale, Wilhelmsen: "Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence." in: Pharmacogenetics and genomics, Vol. 15, Issue 2, pp. 115-25, (2005) (PubMed).
Target
CYP2A6
(Cytochrome P450, Family 2, Subfamily A, Polypeptide 6 (CYP2A6))